Edition:
India

Aratana Therapeutics Inc (PETX.OQ)

PETX.OQ on NASDAQ Stock Exchange Global Market

5.08USD
25 Apr 2018
Change (% chg)

$-0.11 (-2.12%)
Prev Close
$5.19
Open
$5.20
Day's High
$5.20
Day's Low
$5.03
Volume
88,495
Avg. Vol
114,688
52-wk High
$7.67
52-wk Low
$3.68

Select another date:

Thu, Apr 5 2018

BRIEF-Engaged Capital Reports 5.2 Pct Stake In Aratana Therapeutics Inc, As Of April 4, 2018 SEC Filing

* ENGAGED CAPITAL LLC SAYS PURCHASED ARATANA THERAPEUTICS' SHARES BASED ON BELIEF THAT THE SHARES, WHEN PURCHASED, WERE UNDERVALUED

BRIEF-Aratana Therapeutics Reports Q4 Loss Per Share $0.37

* ARATANA THERAPEUTICS REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS

BRIEF-Aratana Therapeutics Expands Therapeutic Candidate Pipeline

* ARATANA THERAPEUTICS EXPANDS THERAPEUTIC CANDIDATE PIPELINE

BRIEF-Elanco, Aratana Announce Marketing Authorization Of Galliprant In Europe

* ELANCO, ARATANA ANNOUNCE MARKETING AUTHORIZATION OF GALLIPRANT® (GRAPIPRANT TABLETS) IN EUROPE Source text for Eikon: Further company coverage:

BRIEF-Aratana Therapeutics Granted Conditional License For A Canine Osteosarcoma Therapeutic

* ARATANA THERAPEUTICS GRANTED CONDITIONAL LICENSE FOR A CANINE OSTEOSARCOMA THERAPEUTIC

BRIEF-Aratana Therapeutics Says Study Did Not Achieve Protocol-Defined Efficacy Success Criteria

* ARATANA THERAPEUTICS INC - ARATANA'S LICENSE PARTNER RESPONSIBLE FOR DEVELOPMENT OF AT-016 SHARED RESULTS OF A PIVOTAL STUDY

BRIEF-Aratana Therapeutics Announces Proposed Public Offering

* ARATANA THERAPEUTICS, INC. ANNOUNCES PROPOSED PUBLIC OFFERING

BRIEF-ELANCO, ARATANA ANNOUNCE POSITIVE OPINION ON GALLIPRANT IN EUROPE

* ELANCO, ARATANA ANNOUNCE POSITIVE OPINION ON GALLIPRANT® (GRAPIPRANT TABLETS) IN EUROPE

BRIEF-Aratana Therapeutics reports Q3 loss per share of $0.21

* Aratana Therapeutics reports third quarter 2017 financial results

Select another date: